ReviewCancer gene therapy2015
Towards a commercial process for the manufacture of genetically modified T cells for therapy.
Review in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed.
- Performance of a modular robotic cluster matches skilled human operators for complex cell therapy manufacturing tasks.International journal of pharmaceutics: X · 2026Article
- Inventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networks.Biotechnology and bioengineering · 2026Article
- Rewiring immunity with in vivo CAR T cell engineering.Nature cancer · 2026Review
- Autofluorescence lifetime imaging resolves cell heterogeneity within peripheral blood mononuclear cells.Biophotonics discovery · 2026Article
- Design principles of nanomaterials for cancer immunotherapy: a mechanistic framework across the cancer immunity cycle.Cancer biology & medicine · 2026Review
- A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.Molecular therapy. Advances · 2026Article
- Autofluorescence lifetime imaging resolves cell heterogeneity within peripheral blood mononuclear cells.bioRxiv : the preprint server for biology · 2026Article
- Cultivation strategy optimisation for NK-92 cell line expansion in static conditions.BMC biotechnology · 2026Article
- Review
- Modulation of the JAK2-STAT3 pathway promotes expansion and maturation of human iPSC-derived myogenic progenitor cells.Stem cell reports · 2025Article
- Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells.Science advances · 2025Article
- Treg cell therapy manufacturability: current state of the art, challenges and new opportunities.Frontiers in immunology · 2025Review
- GMP Manufacturing of Allogenic iPSC-NK Cells for Immunotherapy.Advances in experimental medicine and biology · 2025Review
- Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.Nature biomedical engineering · 2024Article
- Non-viral targeted insertion of large payloads into T cells.Nature biomedical engineering · 2024Article
- Label-free ghost cytometry for manufacturing of cell therapy products.Scientific reports · 2024Article
- Tug of war: Understanding the dynamic interplay of tumor biomechanical environment on dendritic cell function.Mechanobiology in medicine · 2024Review
- Valuation of Medical Innovation Handling with Uncertainty and Risk.Journal of market access & health policy · 2024Article
- The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.Advanced pharmaceutical bulletin · 2024Review
- Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.Molecular therapy. Methods & clinical development · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufacturing of personalized-adoptive T-cell medicinal products. These include closed system operations, improving process robustness and simplifying work flows, reducing labor intensity by implementing process automation, scalability and cost, as well as appropriate testing and tracking of products, all while maintaining strict adherence to Current Good Manufacturing Practices and regulatory guidelines. A decentralized manufacturing model is proposed, where in the future patients' cells could be processed at the point-of-care in the hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.